<p>Recursion Pharmaceuticals, Inc.（纳斯达克代码：RXRX - 获取免费报告）周二股价上涨了 5.4%。该股最高交易价为 5.85 美元，最后交易价为 5.81 美元。在午盘交易中，共成交 3,085,222 股，较平均交易量 11,835,804 股下降了 74%。该股此前收盘价为 5.51 美元。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>突然上升：Recursion Pharmaceuticals 是 NVIDIA 的 AI 宠儿吗？</li>
</ul>
<p>RXRX 已成为多份研究分析报告的主题。Leerink Partners 在 2 月 28 日的报告中将 Recursion Pharmaceuticals 的目标价从 7.00 美元下调至 6.00 美元，并给予该公司 “市场表现” 评级。KeyCorp 在 1 月 8 日的报告中将 Recursion Pharmaceuticals 的目标价从 12.00 美元下调至 10.00 美元，并给予该公司 “增持” 评级。Needham &amp; Company LLC 在 4 月 8 日的报告中重申了 “买入” 评级，并将 Recursion Pharmaceuticals 的目标价设定为 11.00 美元。Cowen 在 2 月 28 日的报告中重申了对 Recursion Pharmaceuticals 的 “持有” 评级。最后，摩根士丹利在 4 月 10 日的研究报告中将 Recursion Pharmaceuticals 的目标价从 10.00 美元下调至 8.00 美元，并给予该公司 “等权重” 评级。四位研究分析师对该股给予了持有评级，两位分析师给予了买入评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，共识目标价为 8.20 美元。</p>
<p><strong>获取我们最新的 RXRX 股票分析</strong></p>
<h2>Recursion Pharmaceuticals 股价上涨 0.7%</h2>
<ul>
<li>生物科技的边缘：两只潜力巨大的股票</li>
</ul>
<p>该公司的市值为 22.3 亿美元，市盈率为-3.63，贝塔值为 1.00。该股的 50 日移动平均线为 6.78 美元，200 日移动平均线为 6.82 美元。该公司的债务与股本比率为 0.04，流动比率为 4.35，速动比率为 4.35。</p>
<p>Recursion Pharmaceuticals（纳斯达克代码：RXRX - 获取免费报告）最近于 2 月 28 日发布了其财报。该公司报告本季度每股收益（EPS）为-0.53 美元，低于市场共识预期的-0.36 美元，差额为-0.17 美元。Recursion Pharmaceuticals 的净利润率为-579.52%，股本回报率为-76.56%。该公司本季度的收入为 460 万美元，而分析师预期为 1904 万美元。去年同期，该公司每股收益为-0.42 美元。Recursion Pharmaceuticals 的季度收入较去年同期下降了 57.8%。研究分析师预计 Recursion Pharmaceuticals, Inc.在本年度将发布-1.57 美元的每股收益。</p>
<h2>对 Recursion Pharmaceuticals 的对冲基金观点</h2>
<ul>
<li>AI 制药：通往 AI 驱动药物投资的两条路径</li>
</ul>
<p>一些机构投资者最近调整了对 RXRX 的持股。先锋集团（Vanguard Group Inc.）在第四季度将其在 Recursion Pharmaceuticals 的持股增加了 40.1%。先锋集团目前拥有 34,009,994 股该公司的股票，价值 229,908,000 美元，此前在上个季度增持了 9,737,196 股。软银集团（Softbank Group CORP.）在第四季度新建了对 Recursion Pharmaceuticals 的持仓，价值约 99,152,000 美元。道富集团（State Street Corp）在第三季度将其在 Recursion Pharmaceuticals 的持仓增加了 47.1%。道富集团目前拥有 12,870,272 股该公司的股票，价值 84,815,000 美元，此前在上个季度增持了 4,120,685 股。Novo Holdings A S 在第四季度新建了对 Recursion Pharmaceuticals 的持仓，价值约 68,375,000 美元。最后，Geode Capital Management LLC 在第四季度将其在 Recursion Pharmaceuticals 的持仓增加了 12.1%。Geode Capital Management LLC 目前拥有 6,087,149 股该公司的股票，价值 41,160,000 美元，此前在上个季度增持了 655,238 股。机构投资者和对冲基金持有该公司 89.06% 的股份。</p>
<h2>关于 Recursion Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Recursion Pharmaceuticals, Inc.是一家临床阶段的生物技术公司，通过整合生物学、化学、自动化、数据科学和工程等技术创新，致力于解码生物学，以工业化药物发现。该公司开发的 REC-994 正在进行治疗脑血管畸形的二期临床试验；REC-2282 正在进行治疗神经纤维瘤病 2 型的二期/三期临床试验；REC-4881 正在进行治疗家族性腺瘤性息肉病的一期 b/二期临床试验；REC-3964 正在进行治疗艰难梭状芽胞杆菌感染的一期临床试验；REC-4881 正在进行治疗 AXIN1 或 APC 突变癌症的二期临床试验。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Recursion Pharmaceuticals</li>
<li>如何投资科技股及值得考虑的顶尖科技股</li>
<li>当心 BigBear.ai：内部人士正在出售——你应该买吗？</li>
<li>特殊目的收购公司（SPAC）你需要知道的事项</li>
<li>随着网络威胁环境的扩大，CrowdStrike 股票值得购买</li>
<li>股票情绪分析：它是如何工作的</li>
<li>国会！在关税引发的崩溃中，谁交易了什么</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Recursion Pharmaceuticals 吗？</h2>
<p>在考虑 Recursion Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Recursion Pharmaceuticals 并不在名单上。</p>
<p>虽然 Recursion Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RXRX

<p>Recursion Pharmaceuticals（纳斯达克代码：RXRX）股价上涨 5.4%，至 5.81 美元，尽管交易量大幅下降。分析师意见不一，目标价格范围从 6.00 美元到 11.00 美元不等。该公司报告的季度每股收益为-0.53 美元，未达到预期，且收入同比下降 57.8%。机构投资者持有 89.06% 的股份，显示出强烈的兴趣。Recursion 专注于药物发现，目前有多个候选药物处于不同的临床试验阶段</p>

<p>Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares traded up 5.4% on Tuesday . The stock traded as high as $5.85 and last traded at $5.81. 3,085,222 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 11,835,804 shares. The stock had previously closed at $5.51.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals, Inc.（纳斯达克代码：RXRX - 获取免费报告）周二股价上涨了 5.4%。该股最高交易价为 5.85 美元，最后交易价为 5.81 美元。在午盘交易中，共成交 3,085,222 股，较平均交易量 11,835,804 股下降了 74%。该股此前收盘价为 5.51 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?</li>
</ul>
<div class="lb-trans"><ul>
<li>突然上升：Recursion Pharmaceuticals 是 NVIDIA 的 AI 宠儿吗？</li>
</ul>
</div><p>RXRX has been the subject of several research analyst reports. Leerink Partners reduced their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a &#34;market perform&#34; rating for the company in a report on Friday, February 28th. KeyCorp reduced their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an &#34;overweight&#34; rating for the company in a report on Wednesday, January 8th. Needham &amp; Company LLC reissued a &#34;buy&#34; rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, April 8th. Cowen reaffirmed a &#34;hold&#34; rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, Morgan Stanley reduced their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an &#34;equal weight&#34; rating for the company in a research report on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of &#34;Hold&#34; and a consensus target price of $8.20.</p>
<div class="lb-trans"><p>RXRX 已成为多份研究分析报告的主题。Leerink Partners 在 2 月 28 日的报告中将 Recursion Pharmaceuticals 的目标价从 7.00 美元下调至 6.00 美元，并给予该公司 “市场表现” 评级。KeyCorp 在 1 月 8 日的报告中将 Recursion Pharmaceuticals 的目标价从 12.00 美元下调至 10.00 美元，并给予该公司 “增持” 评级。Needham &amp; Company LLC 在 4 月 8 日的报告中重申了 “买入” 评级，并将 Recursion Pharmaceuticals 的目标价设定为 11.00 美元。Cowen 在 2 月 28 日的报告中重申了对 Recursion Pharmaceuticals 的 “持有” 评级。最后，摩根士丹利在 4 月 10 日的研究报告中将 Recursion Pharmaceuticals 的目标价从 10.00 美元下调至 8.00 美元，并给予该公司 “等权重” 评级。四位研究分析师对该股给予了持有评级，两位分析师给予了买入评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，共识目标价为 8.20 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on RXRX</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 RXRX 股票分析</strong></p>
</div><h2>Recursion Pharmaceuticals Stock Up 0.7 %</h2>
<div class="lb-trans"><h2>Recursion Pharmaceuticals 股价上涨 0.7%</h2>
</div><ul>
<li>Biotechs on the Brink: 2 Stocks With Huge Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技的边缘：两只潜力巨大的股票</li>
</ul>
</div><p>The company has a market cap of $2.23 billion, a P/E ratio of -3.63 and a beta of 1.00. The stock has a 50-day moving average of $6.78 and a 200 day moving average of $6.82. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.</p>
<div class="lb-trans"><p>该公司的市值为 22.3 亿美元，市盈率为-3.63，贝塔值为 1.00。该股的 50 日移动平均线为 6.78 美元，200 日移动平均线为 6.82 美元。该公司的债务与股本比率为 0.04，流动比率为 4.35，速动比率为 4.35。</p>
</div><p>Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. During the same quarter in the previous year, the firm posted ($0.42) earnings per share. Recursion Pharmaceuticals's quarterly revenue was down 57.8% compared to the same quarter last year. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals（纳斯达克代码：RXRX - 获取免费报告）最近于 2 月 28 日发布了其财报。该公司报告本季度每股收益（EPS）为-0.53 美元，低于市场共识预期的-0.36 美元，差额为-0.17 美元。Recursion Pharmaceuticals 的净利润率为-579.52%，股本回报率为-76.56%。该公司本季度的收入为 460 万美元，而分析师预期为 1904 万美元。去年同期，该公司每股收益为-0.42 美元。Recursion Pharmaceuticals 的季度收入较去年同期下降了 57.8%。研究分析师预计 Recursion Pharmaceuticals, Inc.在本年度将发布-1.57 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Recursion Pharmaceuticals</h2>
<div class="lb-trans"><h2>对 Recursion Pharmaceuticals 的对冲基金观点</h2>
</div><ul>
<li>AI Pharma: 2 Paths to AI-Powered Drug Investment</li>
</ul>
<div class="lb-trans"><ul>
<li>AI 制药：通往 AI 驱动药物投资的两条路径</li>
</ul>
</div><p>A number of institutional investors have recently modified their holdings of RXRX. Vanguard Group Inc. raised its stake in Recursion Pharmaceuticals by 40.1% during the fourth quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock worth $229,908,000 after acquiring an additional 9,737,196 shares in the last quarter. Softbank Group CORP. acquired a new position in Recursion Pharmaceuticals during the 4th quarter worth approximately $99,152,000. State Street Corp increased its position in Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company's stock worth $84,815,000 after purchasing an additional 4,120,685 shares in the last quarter. Novo Holdings A S acquired a new stake in Recursion Pharmaceuticals in the fourth quarter valued at approximately $68,375,000. Finally, Geode Capital Management LLC grew its stake in shares of Recursion Pharmaceuticals by 12.1% during the fourth quarter. Geode Capital Management LLC now owns 6,087,149 shares of the company's stock worth $41,160,000 after buying an additional 655,238 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者最近调整了对 RXRX 的持股。先锋集团（Vanguard Group Inc.）在第四季度将其在 Recursion Pharmaceuticals 的持股增加了 40.1%。先锋集团目前拥有 34,009,994 股该公司的股票，价值 229,908,000 美元，此前在上个季度增持了 9,737,196 股。软银集团（Softbank Group CORP.）在第四季度新建了对 Recursion Pharmaceuticals 的持仓，价值约 99,152,000 美元。道富集团（State Street Corp）在第三季度将其在 Recursion Pharmaceuticals 的持仓增加了 47.1%。道富集团目前拥有 12,870,272 股该公司的股票，价值 84,815,000 美元，此前在上个季度增持了 4,120,685 股。Novo Holdings A S 在第四季度新建了对 Recursion Pharmaceuticals 的持仓，价值约 68,375,000 美元。最后，Geode Capital Management LLC 在第四季度将其在 Recursion Pharmaceuticals 的持仓增加了 12.1%。Geode Capital Management LLC 目前拥有 6,087,149 股该公司的股票，价值 41,160,000 美元，此前在上个季度增持了 655,238 股。机构投资者和对冲基金持有该公司 89.06% 的股份。</p>
</div><h2>About Recursion Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Recursion Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals, Inc.是一家临床阶段的生物技术公司，通过整合生物学、化学、自动化、数据科学和工程等技术创新，致力于解码生物学，以工业化药物发现。该公司开发的 REC-994 正在进行治疗脑血管畸形的二期临床试验；REC-2282 正在进行治疗神经纤维瘤病 2 型的二期/三期临床试验；REC-4881 正在进行治疗家族性腺瘤性息肉病的一期 b/二期临床试验；REC-3964 正在进行治疗艰难梭状芽胞杆菌感染的一期临床试验；REC-4881 正在进行治疗 AXIN1 或 APC 突变癌症的二期临床试验。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Recursion Pharmaceuticals</li>
<li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li>
<li>Beware of BigBear.ai: Insiders Are Selling—Should You?</li>
<li>Special Purpose Acquisition Company (SPAC) What You Need to Know</li>
<li>CrowdStrike Stock is a Buy as Cyberthreat Environment Expands</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>Congress! Who Traded What During the Tariff-Induced Meltdown</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Recursion Pharmaceuticals</li>
<li>如何投资科技股及值得考虑的顶尖科技股</li>
<li>当心 BigBear.ai：内部人士正在出售——你应该买吗？</li>
<li>特殊目的收购公司（SPAC）你需要知道的事项</li>
<li>随着网络威胁环境的扩大，CrowdStrike 股票值得购买</li>
<li>股票情绪分析：它是如何工作的</li>
<li>国会！在关税引发的崩溃中，谁交易了什么</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Recursion Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Recursion Pharmaceuticals 吗？</h2>
</div><p>Before you consider Recursion Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Recursion Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Recursion Pharmaceuticals 并不在名单上。</p>
</div><p>While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Recursion Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Recursion Pharmaceuticals（纳斯达克股票代码：RXRX）股价上涨 5.4% - 现在是买入的好时机吗？